INTRODUCTION
The skeletal abnormalities found in chronic renal failure are collectively termed renal osteodystrophy or renal bone disease. These include parathyroid bone disease, osteomalacia, osteoporosis, osteonecrosis, osteosclerosis and periosteal new bone formation. The pathogenesis of these disorders has been greatly clarified since the inception of regular dialysis programmes for treatment, with the result that treatment strategies have become defined more accurately and in some instances have proved more successful.' -4 This article considers the bone disease related to increased secretion of parathyroid hormone which gives rise to parathyroid bone disease or osteitis fibrosa. Abnormalities in parathyroid function have been known to occur in renal failure since the turn of the century,5 but, in the earlier reported cases, significant clinical problems were rare, except in children.6'7 It was only with the development of supportive treatments for renal failure, such as dialysis and transplantation, that patients survived long enough to develop symptomatic bone disease. This in turn provided a major stimulus to understand the disorder, even though hyperparathyroid bone disease is not exclusive to renal failure.
THE NATURE OF HYPERPARATHYROID BONE DISEASE
Bone is a self-repairing tissue and normally undergoes a sequence of cellular events to ensure that skeletal mass and architecture are maintained. 8 In the adult skeleton, this process is termed 'remodelling' and comprises three phases which occur on the trabecular surfaces of bone. The first is the resorption of a packet of mineralised bone by the action of bone resorbing cells, the osteoclasts, and takes one or two weeks to be completed. Following the completion of a resorption cavity, osteoclasts leave the bone surface and are replaced by osteoblasts which lay down unmineralised bone matrix (osteoid) in an orderly lamellar array at the site of previous bone resorption. Some osteoblasts become trapped within the osteoid matrix to form osteocytes, and it is thought that these are responsible for the third phase of bone remodelling which is the mineralisation of this organic collagen matrix. The remodelling sequence is therefore a phenomenon occurring at bone surfaces and does not take place at the same rate in all parts of the skeleton. For example, bone turnover is more rapid in trabecular bone than in cortical bone where the surface-to-volume ratio is low. Parathyroid hormone is an important activator of this remodelling sequence. In the presence of high secretion rates of parathyroid hormone, the frequency of activation of these remodelling packets is increased.8 The histological consequences are that an increased proportion of the bony surface is involved in both resorption and formation and less of the bone surface is resting. The rapid rates of bone resorption are associated with irregular excavations on the bone surface which can be detected histologically. Local imbalances in formation and resorption may result in patchy osteopenia, particularly of cortical bone. A further consequence of rapid rates of bone remodelling is that new bone formed is laid down in a haphazard fashion rather than in an orderly lamellar array (woven osteoid). This calcifies gradually to form woven bone occupying a relatively large volume, and the total bone volume may increase in hyperparathyroid bone disease so that osteosclerosis and osteoporosis co-exist in the same patient. These consequences of increased bone turnover impair both the structure and the mechanical properties of bone. An additional consequence of increased bone resorption is the deposition of fibrous tissue within the marrow cavity giving rise to the term 'osteitis fibrosa' for hyperparathyroid bone disease (Fig 1) . 
FEATURES OF HYPERPARATHYROID BONE DISEASE
Osteosclerosis is frequently noted in skeletal radiographs, particularly in the spine (Fig 2) , but the characteristic radiographic feature of hyperparathyroid bone disease is subperiosteal erosion of bone. Erosions are found most frequently in the radial borders of the phalanges, the distal ends of the clavicles and the terminal phalanges (Fig 3) . Gross erosion of the terminal phalanges (acro-osteolysis) may result in the collapse of soft tissue, normally supported by bone, giving rise to the appearance of pseudo-clubbing. In children, erosions are commonly found in the metaphyseal region of long bones where the rate of bone remodelling is high (Fig 4) . Periosteal new bone formation is a less common feature in renal hyperparathyroidism ( Fig 5) . Plasma or serum alkaline phosphatase activity is a useful biochemical marker of bone remodelling, since the bone-derived fraction reflects the numbers of active osteoblasts. Plasma hydroxyproline, reflecting in part bone collagen destruction by osteoclasts, may also be used as a biochemical marker, but in renal hyperparathyroidism resorption and formation are both increased to a similar extent, and there is little advantage in measuring both, except for the investigation of treatment regimes.9
Clinically, hyperparathyroid bone disease may give rise to bone pain, tenderness and to muscle weakness. Children and adolescents are affected more frequently and more severely than adults. Metaphyseal erosions in the growing skeleton seen on x-rays may bear some resemblance to rickets (Fig 6) , but may give rise to marked skeletal deformities (Fig 7) . It is for these reasons that almost all the early descriptions of renal bone disease related to children and adolescents. Symptomatic bone disease occurring before end-stage chronic renal failure is relatively uncommon in adults 10 and suggests the presence of additional disorders interfering with skeletal metabolism, such as nutritional deficiency of vitamin D. The prevalence of hyperparathyroid bone disease in patients reaching end-stage chronic renal failure depends on the criteria used for diagnosis. The bones of most patients show some changes of hyperparathyroidism when examined microscopically as judged by increased numbers of bone-forming and boneresorbing cells, but only 30-40% have significant degrees of osteitis fibrosa. Less have radiographic changes and a small minority have symptoms. In patients maintained on haemodialysis treatment the incidence rises, but symptoms are still confined to a minority in most dialysis centres (10-15 % 
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The Ulster Medical Journal THERAPEUTIC APPROACHES Haemodialysis and chronic peritoneal dialysis provide the opportunity for manipulating the biochemical environment, which can modify bone disease. In many instances hyperparathyroid bone disease may regress, but sometimes at the expense of other forms of bone disease. With respect to skeletal metabolism, the institution of dialysis results in an increase in serum calcium and a decrease in serum phosphate towards normal values. Adequate control of serum phosphate may not be achievable by dialysis alone and often requires the use of antacids such as aluminium hydroxide which bind phosphate in the gut and render it unavailable for absorption. Despite these dramatic biochemical improvements, hyperparathyroid bone disease increases both in severity and frequency with increased duration of dialysis (Fig 9) in most renal units (except those in which aluminium toxicity is endemic). The normalisation of serum calcium might be expected to suppress PTH secretion, and in the short term it appears to do so. Thus, after patients have begun regular haemodialysis, plasma values of alkaline phosphatase decrease towards normal, and sub-periosteal erosions may heal. These improvements are, however, transient, and bone disease tends to recur despite the maintenance of normocalcaemia. A similar approach has been to increase serum calcium values above normal by the use of high concentrations of calcium in the dialysis fluid. (Fig 1 0) 
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The Ulster Medical Journal partial parathyroidectomy may be preferable to removal of all parathyroid tissue. However, the long-term follow-up of patients following partial parathyroidectomy indicates that this treatment, like many others for hyperparathyroid bone disease, has transient effects, and bone disease tends to recur despite the concurrent use of vitamin D and the maintenance of normocalcaemia. 30 The remission period is probably longer than that observed in patients treated with vitamin D preparations alone. One of the reasons for avoiding total parathyroidectomy is that this may precipitate a refractory form of vitamin D-resistant osteomalacia,31 similar to that observed in patients with aluminium retention. A partial or transient suppression of hyperparathyroidism in dialysis-treated patients therefore seems possible to achieve in a number of ways. These include phosphate restriction, the infusion of calcium via the dialysate, the use of vitamin D derivatives or parathyroidectomy. Despite the efficacy of these methods, bone disease tends to recur, and it is clear that in dialysis patients there remains a potent stimulus to the growth of parathyroid tissue in addition to low values of serum calcium. The vigour with which parathyroid tissue continues to grow has been demonstrated in studies of auto-transplanted parathyroid tissue removed from patients with hyperplastic glands and embedded in sternomastoid or forearm muscles. Such transplanted tissue may become disseminated and histologically demonstrate paramalignant behaviour by locally invading blood vessels and muscle tissue.32,33 The nature of this stimulus to parathyroid growth is not known. Research of this aspect of parathyroid function is in its infancy and provides one of the challenges for the future.
